Background: Biological aging may be a robust biomarker of dementia or cognitive
performance. This systematic review synthesized the evidence for an association between …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and represents the
leading cause of cognitive impairment and dementia in older individuals throughout the …

Background Growing evidence has demonstrated that DNA methylation (DNAm) plays an
important role in Alzheimer's disease (AD) and that DNAm differences can be detected in the …

To better understand DNA methylation in Alzheimer's disease (AD) from both mechanistic
and biomarker perspectives, we performed an epigenome-wide meta-analysis of blood DNA …

Background Sex is increasingly recognized as a significant factor contributing to the
biological and clinical heterogeneity in AD. There is also growing evidence for the prominent …

Alzheimer's disease (AD) represents the most common form of dementia and affects million
people worldwide, with a high social burden and considerable economic costs. AD …

Dementia and cognitive disorders are major aging-associated pathologies. The prevalence
and severity of these conditions are influenced by both genetic and environmental factors …

Although abnormal accumulation of amyloid in the brain is an early biomarker of Alzheimer's
disease (AD), wide variation in cognitive trajectories during life can be seen in the setting of …

Traditional approaches for diagnosing Alzheimer's disease (AD) such as brain imaging and
cerebrospinal fluid are invasive and expensive. It is desirable to develop a useful diagnostic …

Introduction Identifying reliable biomarkers that reflect cancer survivorship symptoms
remains a challenge for researchers. DNA methylation (DNAm) measurements reflecting …